How do you approach adjuvant therapy for a resected gastric GIST when the risk for recurrence is discordant between various prediction tools?

For intermediate risk patients, I generally have a discussion with the patient surrounding the risk of recurrence vs the potential toxicity of adjuvant therapy. Some patients will opt for surveillance and others will be more comfortable starting adjuvant imatinib. A nomogram that I find especially h...